Orphan designation: Pemafibrate Treatment of primary biliary cholangitis, 25/07/2023 Positive
Orphan designation: Pemafibrate Treatment of primary biliary cholangitis, 25/07/2023 Positive
Orphan designation: Pemafibrate Treatment of primary biliary cholangitis, 25/07/2023 Positive
Orphan designation: ulviprubart Treatment of inclusion body myositis, 25/07/2023 Positive
European Medicines Agency (EMA) and Federation of Veterinarians of Europe (FVE) info session on the UPD public portal, Online, European Medicines Agency, Amsterdam, the Netherlands, from 21 February 2024, 15:00 (CET) to 21 February 2024, 16:30 (CET)
We are deeply saddened to announce the passing of Prof. Werner Bauer, key figure in the history and development of (EFIM). Prof. Bauer served as EFIM President from 2008 to 2010 and played an instrumental role in shaping the Federation into what it is today.
Prof. Bauer was actively involved with the European Board of Internal Medicine and worked on launching the European Curriculum in Internal Medicine and actively served EFIM Executive Committee between 2006 - 2012.
Human medicines European public assessment report (EPAR): Lopinavir/Ritonavir Mylan, lopinavir,ritonavir, Date of authorisation: 14/01/2016, Revision: 17, Status: Authorised
Veterinary medicines European public assessment report (EPAR): Chanaxin, tulathromycin, Status: Authorised
Opinion/decision on a Paediatric investigation plan (PIP): Pifeltro, doravirine, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infectious diseases, PIP number: P/0505/2022
Opinion/decision on a Paediatric investigation plan (PIP): Delstrigo, doravirine,lamivudine,tenofovir disoproxil (fumarate), decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infectious diseases, PIP number: P/0504/2022
Final programming document 2024-2026
Annual reports and work programmes